Alfasigma S.p.A.

• Safety, tolerability, pharmacokinetics, and efficacy of filgotinib for the treatment of polyarticular-course juvenile idiopathic arthritis i… Recruiting
  2024-511593-70-00 Phase III 10 countries FILGOTINIB
• Open-label extension study with filgotinib in children with juvenile idiopathic arthritis. Recruiting
  2025-523239-21-00 Phase III 2 countries FILGOTINIB
• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis Recruiting
  2024-511458-32-00 Phase III 12 countries FILGOTINIB
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 Phase III 15 countries FILGOTINIB
• Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131 Ended
  2023-505844-21-00 Phase I (Other) 4 countries FILGOTINIB
• A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis Ended
  2024-516199-14-00 Phase III 1 country FILGOTINIB
• A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATIO… Ended
  2024-513988-70-00 Phase I (Other) 1 country
• A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis Ended
  2024-513919-27-00 Phase III 3 countries FILGOTINIB

Showing 1–8 of 8 trials